141
Views
14
CrossRef citations to date
0
Altmetric
Original Articles

Suppression of Inducible Nitric Oxide Synthase and Cyclooxygenase-2 Expression in Raw 264.7 Macrophages by Sesquiterpene Lactones

, , , , &
Pages 2119-2131 | Published online: 06 Feb 2008
 

Abstract

The molecular mechanism underlying the suppression of lipopolysaccharide (LPS)/interferon-γ (IFN-γ)-induced nitric oxide (NO) and prostaglandin (PG) E2 production was investigated in RAW 264.7 macrophages treated with sesquiterpene lactones, zaluzanin-C and estafiatone, isolated from Ainsliaea. Zaluzanin-C and estafiatone decreased NO production in LPS/IFN-γ-stimulated RAW 264.7 macrophages with an IC50 of about 6.61 μM and 3.80 μM, respectively. In addition, these compounds inhibited the synthesis of PGE2 in LPS/IFN-γ-treated RAW 264.7 macrophages. Furthermore, treatment with zaluzanin-C and estafiatone resulted in a decrease in inducible No Synthase (iNOS) and Cyclooxygenase-2 (COX-2) protein and mRNA expression levels. Zaluzanin-C and estafiatone inhibited nuclear factor-κB (NF-κB) activation, a transcription factor necessary for iNOS and COX-2 expression in response to LPS/IFN-γ. This effect was accompanied by parallel reduction of phosphorylation and degradation of inhibitor of κB (IkB). In addition, these effects were completely blocked by treatment with cysteine, indicating that the inhibitory effect of zaluzanin-C and estafiatone might be mediated by alkylation of either NF-κB itself or an upstream molecule of NF-κB. These results demonstrate that the suppression of NF-κB activation by zaluzanin-C and estafiatone might be attributed to inhibition of nuclear translocation of NF-κB resulting from blockade of the degradation of IκB, leading to suppression of the expression of iNOS and COX-2, which play important roles in inflammatory signaling pathways.

This study was supported by a grant from the Korea Health 21 R&D Project, Ministry of Health and Welfare, Republic of Korea (02-PJ2-PG3-20999-0002).

Sang Gyu Shin and Jae Ku Kang contributed equally to this work.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.